重组人血管内皮抑制素联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响  

Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma

作　　者：郝明志[1] 林海澜[1] 陈起忠[1] 胡育斌[1] 

机构地区：[1]福建省卫生职业技术学院教学医院,福建省肿瘤医院介入科,福建省肿瘤转化医学重点实验室,福州350014

出　　处：《临床肝胆病杂志》2016年第1期92-96,共5页Journal of Clinical Hepatology

摘　　要：目的观察重组人血管内皮抑制素（恩度）联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响。方法选取2011年3月-2015年5月福建省肿瘤医院收治的86例中晚期肝癌患者,按照配对设计分为治疗组和对照组。治疗组（n=43）采用恩度联合肝动脉介入治疗;对照组（n=43）采用肝动脉介入治疗联合口服中药肝复乐。计数资料组间比较采用χ2检验,计量资料组间比较采用t检验。Kaplan-Meier法进行生存分析,单因素分析采用Log-rank法,多因素回归分析采用Cox比例风险模型。结果治疗组和对照组的中位无疾病进展生存期分别为154 d[95%可信区间（95%CI）：94~214 d]、70 d（95%CI：39~101 d）,两组比较差异具有统计学意义（χ2=10.741,P=0.001）。单因素分析显示,肝硬化严重程度、肿瘤个数、门静脉主干癌栓/下腔静脉癌栓是中晚期肝癌患者预后的影响因素（χ2值分别为8.182、9.150、6.565,P值分别为0.004、0.027、0.038）;多因素分析显示,肝硬化严重程度、门静脉主干癌栓/下腔静脉癌栓是恩度联合肝动脉介入治疗影响中晚期肝癌无疾病进展生存期的独立预后因素（P值分别为0.028、0.013）。结论恩度可延长中晚期肝癌介入治疗后的无疾病进展生存期,但对严重肝硬化、门静脉主干癌栓/下腔静脉癌栓患者优势不明显。Objective To investigate the effect of recombinant human endostatin （Endostar） combined with hepatic artery interventional therapy on the progression - free smwival （PFS） of patients with advanced hepatoeellular carcinoma （ HCC ）. Methods A total of 86 patients with advanced HCC who were admitted to Fujian Provincial Tumor Hospital from March 2011 to May 2015 were selected and divided into treatment group and control group according to a matched pair design. The treatment group （43 patients） was given Endostar combined with hepatic artery interventional therapy, and the control group （43 patients） was given hepatic artery interventional therapy combined with oral administration of Ganfule. The ehi - square test was applied for comparison of categorical data between the two groups, and the t - test was applied for comparison of continuous data between the two groups. The Kaplan - Meier method was applied for survival analysis, the Log - rank test was applied for univariate analysis, and Cox proportional hazards model was applied for multivariate analysis. Results The me- dian PFS in the treatment group and the control group was 154 d [ 95% confidence interval （CI） ： 94 -214 d I and 70 d （95% c I： 39 - 101 d） , respectively, with a significant difference between the two groups （X2 = 10. 741, P =0. 001 ）. Univariate analysis showed that the sever- ity of liver cirrhosis, number of tumors, and main portal vein tumor thrombus/inferior vena eava tumor thrombus were the prognostic factors for patients with advanced HCC （χ2 = 8. 182, 9. 150, and 6. 565, P = 0. 004, 0. 027, and 0. 038） ; multivariate analysis showed that the severily of liver cirrhosis and main portal vein tumor thrombus/inferior vena eava tumor thrombus were the independent prognostic factors for PFS in patients with advanced HCC who were treated with Endostar combined with hepatic artery interventional therapy （ P = 0. 028 and 0. 013）. Conclusion Endostar can effectively prolong the PFS of patients with adva

关 键 词：肝肿瘤 化学栓塞 治疗性 化学疗法 肿瘤 局部灌注 血管抑制素类 治疗 

分 类 号：R735.7[医药卫生—肿瘤]